Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective

Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic si...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nutrients 2022-09, Vol.14 (18), p.3774
Hauptverfasser:	Trandafir, Laura M, Dodi, Gianina, Frasinariu, Otilia, Luca, Alina C, Butnariu, Lacramioara I, Tarca, Elena, Moisa, Stefana M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipocytes Adipose tissue Adipose tissues Alzheimer's disease Analysis Blood vessels Body fat Body mass index Cardiovascular disease Care and treatment Chronic illnesses Complications and side effects Diabetes Drug delivery Drug delivery systems Drug therapy Drugs Dyslipidemia Dyslipidemias Exercise Food Functional foods & nutraceuticals Gastrointestinal surgery Health aspects Health care Hypertension Hypotheses Inflammation Insulin Mental health Metabolic disorders Metabolic syndrome Nanotechnology Obesity Overweight Pandemics Physical fitness Review Side effects Standard deviation Technology application Vehicles
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!